Notably, Davison and colleagues (Davison et al. 2014) have reported that, in their series, none of the high-grade mucinous adenocarcinomas with a predominant signet ring cell component had KRAS mutation. This evidence concerns the gene KRAS and mucinous adenocarcinoma.